• london biotech banner
  • Dermatology June 24 Conference
  • Agora
MedEdge MEA MedEdge_Logo_Dark

Public Relations, Top Health Magazine and Healthcare News GCC

  • Newsletters
  • Magazines
  • Subscribe
  • Home
  • News
  • Opinion
  • Interviews
  • Featured
  • Cover Stories
  • Events
  • Health For all
    • Ageing Gracefully
    • Family Health Matters
    • Environment Health
    • Women and Child Health
    • Men’s Health
  • Resource Hub
    • Fresh Perspectives
    • Medical Tourism
    • Medical Education
    • Personnel
    • Research
      • Healthcare Journals & Publishers
    • Healthcare Campaigns
    • Health Tools Hub
    • Dubai Health Centers Directory | Services, Locations & Timings
Reading: AstraZeneca plans $1.5 billion manufacturing facility in Singapore
Share
Notification
  • london biotech banner
  • Dermatology June 24 Conference
  • Agora
MedEdge MEA
  • Magazines
  • Newsletters
  • Profiles
  • Subscribe
Search
  • Home
  • News
  • Opinion
  • Interviews
  • Featured
  • Cover Stories
  • Events
  • Health For all
    • Ageing Gracefully
    • Family Health Matters
    • Environment Health
    • Women and Child Health
    • Men’s Health
  • Resource Hub
    • Fresh Perspectives
    • Medical Tourism
    • Medical Education
    • Personnel
    • Research
    • Healthcare Campaigns
    • Health Tools Hub
    • Dubai Health Centers Directory | Services, Locations & Timings
Have an existing account? Sign In
MedEdge MEA > News > AstraZeneca plans $1.5 billion manufacturing facility in Singapore
NewsLead

AstraZeneca plans $1.5 billion manufacturing facility in Singapore

ME Desk
ME Desk
Published: May 21, 2024
Share
3 Min Read
AstraZeneca plans $1.5B manufacturing facility in Singapore
SHARE

20 May 2024- AstraZeneca intends to build a $1.5 billion manufacturing facility in Singapore for antibody drug conjugates (ADCs), enhancing global supply of its ADC portfolio. ADCs are next-generation treatments that deliver highly potent cancer-killing agents directly to cancer cells through a targeted antibody.

Moreover, The planned greenfield facility, supported by the Singapore Economic Development Board (EDB), will be AstraZeneca’s first end-to-end ADC production site, fully incorporating all steps of the manufacturing process at a commercial scale. Manufacturing of ADCs is a multi-step process that comprises antibody production, synthesis of chemotherapy drug and linker, conjugation of drug-linker to the antibody, and filling of the completed ADC substance.

Also Read: AstraZeneca increases 2024 dividend by 7%

Png Cheong Boon, Chairman, EDB said: “We welcome AstraZeneca’s decision to establish a manufacturing presence in Singapore for the first time. It will also be a first for AstraZeneca – an end-to-end manufacturing facility for novel antibody drug conjugates that enables precision therapy for cancer. This greenfield investment is a strong show of confidence in Singapore’s biopharmaceutical manufacturing capabilities and talent, strengthens our ecosystem in supporting the development and manufacturing of precision medicines, and creates meaningful jobs and economic opportunities for Singapore. We look forward to a successful partnership with AstraZeneca.”

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “AstraZeneca has built an industry-leading portfolio of cancer medicines including antibody drug conjugates which have shown enormous potential to replace traditional chemotherapy for patients across many settings. Singapore is one of the world’s most attractive countries for investment given its reputation for excellence in complex manufacturing, and I am excited for AstraZeneca to locate our $1.5 billion ADC manufacturing facility in the country.”

However, AstraZeneca has a broad portfolio of in-house ADCs including six wholly owned ADCs in the clinic and many more in preclinical development.

As part of AstraZeneca’s commitment to driving sustainability in healthcare, the Company will work with Singapore’s government and other partners on green solutions for the ADC facility. This facility will emit zero carbon from its first day of operations.

Furthermore, AstraZeneca aims to begin design and construction of the manufacturing facility by the end of 2024, with targeted operational readiness from 2029.

Share This Article
Facebook Whatsapp Whatsapp LinkedIn Copy Link
Share
Previous Article MoHAP UAE launches National Survey for Health and Nutrition 2024 MoHAP UAE launches National Survey for Health and Nutrition 2024
Next Article UAE Residents Travelling to Saudi for Umrah-Hajj? Here's what you need to know About the Vaccine You Need to Take Important Deadline Approaching: Domestic Hajj Pilgrims Must Complete Vaccinations

Recent Posts

  • NMSS AND ERTH ZAYED PHILANTHROPIES SIGN AED 25 MILLION GRANT AGREEMENT TO MARK WORLD MS DAY
  • Liver Transplantation Enters the Era of Precision Diagnostics
  • Merck Gulf & Ovasave Host Women’s Health Forum in UAE
  • Inside Cleveland Clinic Abu Dhabi’s Heart Institute with Dr. Gopal Bhatnagar
  • Global Health Collaboration in Focus: Malek El Husseini at Abu Dhabi Global Health Week 2025
  • Dermatology expo rome
  • LifeSpin
  • Health ExpoIraq
  • Agora
Two Point Five Logo white
  • About Us
  • Terms and Conditions
  • Privacy Policy
  • Submit Your Story
  • Contact Us
  • MediaKit
Reading: AstraZeneca plans $1.5 billion manufacturing facility in Singapore
Share

Published by Two Point Five Media FZCO

  • About Us
  • Terms and Conditions
  • Privacy Policy
  • Submit Your Story
  • Contact Us
  • MediaKit
Reading: AstraZeneca plans $1.5 billion manufacturing facility in Singapore
Share

Follow US on Social Media

Facebook Instagram Linkedin X-twitter Youtube Whatsapp
Logo of Medede mea
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?